Cytokine release syndrome
MONDO:0600008A syndrome that occurs after therapeutic infusion of antibodies into the blood and is characterized by nausea, headache, tachycardia, hypotension, rash, and shortness of breath. It is caused by the release of cytokines from the cells that are targeted by the antibodies. Most patients experience a mild to moderate reaction; however, the reaction may be severe and life-threatening.
Also known as: CRS, cytokine storm, cytokine-associated toxicity
36 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Can a drug stop dangerous side effects of new myeloma therapies?
Disease control Not yet recruitingThis phase 2 trial tests whether infliximab, a drug that blocks inflammation, can prevent cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma receiving teclistamab or talquetamab. CRS is a common and sometimes serious side effect of these treatm…
Phase: PHASE2 • Sponsor: Naresh Bumma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a Pre-Dose prevent a dangerous reaction in multiple myeloma treatment?
Disease control Not yet recruitingThis study tests whether giving tocilizumab before the first dose of linvoseltamab can lower the risk of cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma. The 30 participants have already tried at least four prior treatments. Researchers will…
Phase: PHASE4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope: drug may prevent dangerous reactions to cancer immunotherapy
Disease control Not yet recruitingThis study tests whether the drug emapalumab can prevent severe side effects (cytokine release syndrome and nerve-related toxicity) in people with lymphoma or multiple myeloma receiving bispecific antibody therapy. About 60 adults will take emapalumab before their cancer treatmen…
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Timing is everything: new trial aims to save lives from immune storm
Disease control Not yet recruitingThis study compares two strategies for starting the drug etoposide in adults with severe hemophagocytic lymphohistiocytosis (HLH) who are in the intensive care unit. HLH is a life-threatening overreaction of the immune system that can cause organ failure. The goal is to see if gi…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New CAR t therapy targets two proteins to fight blood cancers
Disease control Not yet recruitingThis early-phase trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD20) on B cell cancer cells. It is for adults with B cell leukemia or lymphoma who have run out of standard options, including commercial CAR T cells. The main goal is to check safe…
Phase: PHASE1 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New device aims to tame inflammation in Kids' heart surgery
Knowledge-focused Not yet recruitingThis study tests a special filter (Jafron HA-60) used during heart-lung bypass in 20 children having open-heart surgery. The filter is designed to remove inflammatory substances from the blood, which may help reduce complications. The main goal is to see if using the filter is sa…
Phase: NA • Sponsor: Centre Hospitalier Universitaire Vaudois • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC